我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
30
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
25
83.3%
尚未招募
3
10.0%
招募中
2
6.7%
暂无批准数据
- Cordis has launched the SELUTION SLR PTA Drug-Eluting Balloon in Japan, marking the first sirolimus-eluting balloon approved for peripheral artery disease treatment in the country. - The SELUTION SFA Japan clinical trial demonstrated impressive three-year outcomes with 81.5% primary patency and 93.8% of patients remaining free from reintervention. - The device features Sustained Limus Release technology designed to provide controlled sirolimus delivery over 90 days to reduce restenosis and restore vessel function. - Cordis will present additional clinical data from the SELUTION4ISR and SELUTION DeNovo coronary trials at CRT 2026, including 12-month outcomes and procedural experience analyses.
